A new drug could be the beginning of the end for sleeping sickness

March 16, 2026 - 20:45

A significant breakthrough has been announced in the decades-long battle against human African trypanosomiasis, commonly known as sleeping sickness. Health officials are now expressing renewed hope that the disease could be eliminated by 2030, thanks to the development of a highly effective new treatment.

This oral medication, called acoziborole, has demonstrated exceptional results in late-stage clinical trials. Administered as a single dose, it represents a dramatic improvement over previous therapies, which often required complex and painful intravenous infusions in a hospital setting. The simplicity of the new drug could revolutionize treatment, making it far easier to deliver in the remote, rural areas of sub-Saharan Africa where the disease is endemic.

Sleeping sickness, transmitted by the tsetse fly, is fatal if left untreated. It progresses from fever and headaches to severe neurological disruption, including the sleep-cycle disturbances that give the illness its name. For years, eradication efforts have been hampered by difficult diagnostics and cumbersome treatments.

The successful trial results mark a pivotal moment. With its high efficacy and patient-friendly administration, this new drug is poised to become a cornerstone of elimination strategies, bringing the goal of consigning sleeping sickness to the history books firmly within reach.